Hiroyuki Okabe

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

Nozomu Tanaka, Kazuki Sakamoto, Hiroyuki Okabe et al. · Oncology Reports · 2014 · 140 citations · Full text

Antitumor Activity, Medicine, Tumor Growth +14

Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts

Hiroshi Tsukihara, Fumio Nakagawa, Kazuki Sakamoto et al. · Oncology Reports · 2015 · 109 citations · Full text

Combination Chemotherapy, Medicine, Pharmacology +12

Dihydropyrimidine Dehydrogenase and Messenger RNA Levels in Gastric Cancer: Possible Predictor for Sensitivity to 5‐Fluorouracil

Yoichiro Ishikawa, Tetsuro Kubota, Yoshihide Otani et al. · Japanese Journal of Cancer Research · 2000 · 93 citations · Full text

Advanced Gastric Cancer, Gastroenterology, Pathology +16

Granulocyte proteases and hydrogen peroxide synergistically inactivate thrombomodulin of endothelial cells in vitro.

Hiroki Abe, Kenji Okajima, Hiroyuki Okabe et al. · PubMed · 1994 · 86 citations

An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA

Tomohiro Emura, Fumio Nakagawa, Akio Fujioka et al. · International Journal of Molecular Medicine · 2004 · 85 citations

Pharmaceutical Science, Chemical Biology, Culture Medium +21